Pharmacokinetics of oltipraz after intravenous and oral administration in rats with dehydration for 72 hours

Biopharmaceutics and Drug Disposition

Volumn 26, Issue 2, 2005, Pages 77-83

  Bae, Soo K ^a   Lee, Shin J ^a   Kim, Jin W ^b   Kim, Young H ^b   Kim, Sang G ^a   Lee, Myung G ^a  

^a Seoul National University   (South Korea)

^b CJ Corporation   (South Korea)

Author keywords

Oltipraz; Pharmacokinetics; Rats; Water deprivation

Indexed keywords

OLTIPRAZ; WATER;

ANTINEOPLASTIC ACTIVITY; ANTIVIRAL ACTIVITY; AREA UNDER THE CURVE; ARTICLE; CONTROLLED STUDY; DEHYDRATION; DRUG ABSORPTION; DRUG CLEARANCE; DRUG DISPOSITION; DRUG DISTRIBUTION; DRUG HALF LIFE; DRUG METABOLISM; DRUG PROTEIN BINDING; EQUILIBRIUM DIALYSIS; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; MALE; MEAN RESIDENCE TIME; NONHUMAN; PLASMA PROTEIN BINDING; RAT; STEADY STATE; TOTAL BODY WATER; WATER DEPRIVATION;

ADMINISTRATION, ORAL; ANIMALS; ANTICARCINOGENIC AGENTS; AREA UNDER CURVE; BLOOD PROTEINS; GASTROINTESTINAL TRACT; INJECTIONS, INTRAVENOUS; INTESTINAL ABSORPTION; MALE; METABOLIC CLEARANCE RATE; PROTEIN BINDING; PYRAZINES; RATS; RATS, SPRAGUE-DAWLEY; TIME FACTORS; WATER DEPRIVATION;

EID: 15544387336     PISSN: 01422782     EISSN: None     Source Type: Journal    
DOI: 10.1002/bdd.433     Document Type: Article

References (17)

1. Clapper M. Chemopreventive activity of oltipraz. Pharmacol Ther 1998; 78: 17-27.
2. Bueding E, Dolan P, Leroy JP. The antischistosomal activity of oltipraz. Res Commun Chem Pathol Pharmacol 1982; 37: 293-303.
3. Primiano T, Egner PA, Sutter TR, Kellof GJ, Roebuds BD, Kensler TW. Intermittent dosing with oltipraz: relationship between chemoprevention of aflatoxin-induced tumorigenesis and induction of glutathione-S-transferases. Cancer Res 1995; 55: 4319-4324.
4. Kang KW, Kim YG, Cho MK, et al. Oltipraz regenerates cirrhotic liver through CCAAT/enhancer binding protein-mediated stellate cell inactivation. FASEB J 2002; 16: 1988-1990.
5. Bakar SK, Niazi S. Effect of water deprivation on aspirin disposition kinetics. J Pharm Sci 1983; 72: 1030-1034.
6. Ha HA, Lee SH, Kim SH, Kim ON, Lee MG. Effect of water deprivation for 48 hours on the pharmacokinetics and pharmacodynamics of azosemide in rats. Res Commun Mol Pathol Pharmacol 1996; 93: 109-128.
7. Son IJ, Moon YJ, Lee MG, Shon YT. No effect of water deprivation for 48 hours on the pharmacokinetic of intravenous tacrolimus in rats. Res Commun Mol Pathol Pharmacol 2000; 107: 279-289.
8. Kim SH, Kwon JW, Kim WB, Lee I, Lee MG. Effects of water deprivation for 72 hours on the pharmacokinetics of a new carbapenem, DA-1131, in rats. Life Sci 2002; 71: 2291-2298.
9. Kim SG, Kim EJ, Kim YG, Lee MG. Expression of cytochrome P-450s and glutathione S-transferases in the rat liver during water deprivation: effects of glucose supplementation. J Appl Toxicol 2001; 21: 123-129.
10. Kim SH, Choi YM, Lee MG. Pharmacokinectics and pharmacodynamics of furosemide in protein-calorie malnutrition. J Pharmacokinet Biopharm 1993; 21: 1-17.
11. Bae SK, Bu SC, Kim EJ, Kim SH, Kim SG, Lee MG. Determination of a chemopreventive agent, oltipraz, in rat plasma and urine by high-performance liquid chromatography. Res Commun Mol Pathol Pharmacol 2001; 110: 133-138.
12. Bu SC, Kim EJ, Kim SH, Kim SG, Lee MG. Stability, blood partition and protein binding of an antifibrotic agent, oltipraz. Res Commun Mol Pathol Pharmacol 2001; 109: 333-344.
13. Christensen RG, Malone W. Determination of oltipraz in serum by high-performance liquid chromatography with optical absorbance and mass spectrometric detection. J Chromatogr 1992; 584: 207-212.
14. Lee HJ, Chiou WL. Erythrocytes as barriers for drug elimination in the isolated rat liver. I. Doxorubicin. Pharm Res 1989; 6: 833-839.
15. Lee HJ, Chiou WL. Erythrocytes as barriers for drug elimination in the isolated rat liver. II. Propranolol. Pharm Res 1989; 6: 840-843.
16. Davies B, Morris T. Physiological parameters in laboratory animals and humans. Pharm Res 1993; 10: 1093-1095.
17. Lee MG, Chiou WL. Evaluation of potential causes for the incomplete bioavailability of furosemide: Gastric first-pass metabolism. J Pharmacokinet Biopharm 1983; 11: 623-640.